

Results of General Meeting

A
S
X

R
E
L
E
A
S
E

MGC Pharmaceuticals Ltd (ASX: MXC, ‘MGC Pharma’ or ‘the Company’), would like to confirm the results of the Company’s General Meeting held 2 July 2020 in accordance with Listing Rule 3.13.2. All resolutions put to the meeting were passed on a poll.

Details of the proxy and poll voting on the resolutions are set out in the attached report.

--Ends--

Authorised for issue by Rachel Kerr, Company Secretary, further information, please contact:

PR/IR Advisors – Media & Capital Partners

Melissa Hamilton (PR) +61 417 750 274

Rod Hinchcliffe (IR) +61 412 277 377

Melissa.Hamilton@mcpartners.com.au

Rod.Hinchcliffe@mcpartners.com.au

MGC Pharmaceuticals Ltd

Brett Mitchell

Executive Chairman

+61 8 6382 3390




info@mgcpharma.com.au

About MGC Pharma

MGC Pharmaceuticals Ltd (ASX: MXC) is a European based bio-pharma company developing and supplying affordable standardised phytocannabinoid derived medicines to patients globally. The Company’s founders were key figures in the global medical cannabis industry and the core business strategy is to develop and supply high quality phytocannabinoid derived medicines for the growing demand in the medical markets in Europe, North America and Australasia. MGC Pharma has a robust product offering targeting two widespread medical conditions – epilepsy and dementia – and has further products in the development pipeline.

Employing its ‘Nature to Medicine’ strategy, MGC Pharma has partnered with renowned institutions and academia to optimise cultivation and the development of targeted phytocannabinoid derived medicines products prior to production in the Company’s EU-GMP Certified manufacturing facility. MGC Pharma has a number of research collaborations with world renowned academic institutions, and including recent research highlighting the positive impact of using specific phytocannabinoid formulations developed by MGC Pharma in the treatment of glioblastoma, the most aggressive and so far therapeutically resistant primary brain tumour.

MGC Pharma has a growing patient base in Australia, the UK, Brazil and Ireland and has a global distribution footprint via an extensive network of commercial partners meaning that it is poised to supply the global market.

Follow us through our social media channels    

MGC PHARMACEUTICALS LTD
GENERAL MEETING
Thursday, 02 July 2020
Results of Meeting

The following information is provided in accordance with section 251AA(2) of the Corporations Act 2001 (Cth) and ASX Listing Rule 3.13.2.

Resolution details		Instructions given to validly appointed proxies (as at proxy close)				Number of votes cast on the poll (where applicable)			Resolution Result
Resolution	Resolution Type	For	Against	Proxy's Discretion	Abstain	For	Against	Abstain*	Carried / Not Carried
1 Ratification of Prior Issue of Shares to O.T Capital Modiin Ltd	Ordinary	209,681,394 76.77%	58,633,490 21.47%	4,807,147 1.76%	35,848,288	214,488,541 78.53%	58,633,490 21.47%	35,848,288	Carried
2 Ratification of prior issue of options to SPP Participants	Ordinary	207,943,228 76.82%	54,403,594 20.11%	8,288,253 3.07%	2,108,004	216,231,481 79.90%	54,403,594 20.10%	2,108,004	Carried
3 Ratification of Prior Issue of Shares to Secondary Placement Participants	Ordinary	187,739,030 74.58%	59,075,967 23.47%	4,907,822 1.95%	54,438,241	192,646,852 76.53%	59,075,967 23.47%	54,438,241	Carried
4 Ratification of Prior Issue of Options to Secondary Placement Participants	Ordinary	187,543,625 74.59%	59,008,876 23.48%	4,856,802 1.93%	54,751,757	192,400,427 76.53%	59,008,876 23.47%	54,751,757	Carried
5 Ratification of Prior Issue of Shares to Canaccord	Ordinary	245,738,712 80.20%	55,880,779 18.23%	4,793,802 1.57%	2,557,026	250,532,514 81.76%	55,880,779 18.24%	2,557,026	Carried
6 Ratification of Prior Issue of Shares to Cannvalate Pty Ltd	Ordinary	245,687,837 80.16%	55,925,779 18.25%	4,853,802 1.59%	2,502,901	250,541,639 81.75%	55,925,779 18.25%	2,502,901	Carried
7 Issue of Options to Mr Brett Mitchell - Related Party Participation in SPP	Ordinary	209,863,190 75.84%	61,948,426 22.39%	4,893,802 1.77%	32,264,901	214,756,992 77.61%	61,948,426 22.39%	32,264,901	Carried
8 Issue of Options to Dr Ross Walker - Related Party Participation in SPP	Ordinary	234,966,251 78.25%	60,452,999 20.13%	4,848,802 1.62%	8,702,267	239,815,053 79.87%	60,452,999 20.13%	8,702,267	Carried

* Votes cast by a person who abstains on an item are not counted in calculating the required majority on a poll.